Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $7.1429.
A number of research firms recently issued reports on NMRA. Needham & Company LLC decreased their target price on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Tuesday, April 21st. HC Wainwright decreased their target price on Neumora Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Guggenheim reiterated a “buy” rating and issued a $14.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 31st.
Get Our Latest Research Report on Neumora Therapeutics
Neumora Therapeutics Trading Down 1.9%
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, equities analysts expect that Neumora Therapeutics will post -0.96 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of NMRA. Perceptive Advisors LLC purchased a new position in Neumora Therapeutics in the first quarter valued at $9,953,000. Siren L.L.C. boosted its holdings in Neumora Therapeutics by 35.1% in the first quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after purchasing an additional 2,209,039 shares during the period. Millennium Management LLC lifted its holdings in Neumora Therapeutics by 80.1% during the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after buying an additional 1,608,266 shares during the last quarter. Ikarian Capital LLC lifted its holdings in Neumora Therapeutics by 10,128.9% during the 4th quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock worth $2,288,000 after buying an additional 1,265,910 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Neumora Therapeutics during the 3rd quarter worth about $1,512,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.
About Neumora Therapeutics
Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.
Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.
Featured Stories
- Five stocks we like better than Neumora Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
